| Literature DB >> 29274830 |
Sukhbir S Singh1, Liane Belland2, Nicholas Leyland3, Sarah von Riedemann4, Ally Murji5.
Abstract
Uterine fibroids are common in women of reproductive age and can have a significant impact on quality of life and fertility. Although a number of international obstetrics/gynecology societies have issued evidence-based clinical practice guidelines for the management of symptomatic uterine fibroids, many of these guidelines do not yet reflect the most recent clinical evidence and approved indication for one of the key medical management options: the selective progesterone receptor modulator class. This article aims to share the clinical experience gained with selective progesterone receptor modulators in Europe and Canada by reviewing the historical development of selective progesterone receptor modulators, current best practices for selective progesterone receptor modulator use based on available data, and potential future uses for selective progesterone receptor modulators in uterine fibroids and other gynecologic conditions.Entities:
Keywords: leiomyomas; selective progesterone receptor modulators; ulipristal acetate; uterine fibroids; women’s health
Mesh:
Substances:
Year: 2017 PMID: 29274830 DOI: 10.1016/j.ajog.2017.12.206
Source DB: PubMed Journal: Am J Obstet Gynecol ISSN: 0002-9378 Impact factor: 8.661